Does sitagliptin , an dipeptidyl peptidase-4 inhibitor , alter the pharmacokinetics of the sulphonylurea , glyburide , in healthy subjects?
Sitagliptin does not alter the pharmacokinetics of glyburide in healthy subjects.
Failure to demonstrate any benefit from initial combination therapy may reflect an underpowered rather than a negative study. The distinct impact of late olanzapine augmentation suggests that pretreatment with an antidepressant may be required to facilitate a rapid antidepressant response to combined treatment.